



Dedicated To Life

May 4, 2024

BSE Limited P J Towers, Dalal Street, <u>Mumbai-400001</u>	Code: 532321	National Stock Exchange of India Limited Code: Zyduslife Exchange Plaza, C/1, Block G, Bandra-Kurla Complex, Bandra (East), <u>Mumbai-400051</u>
--	---------------------	--

Re.: Acquisition of worldwide proprietary rights to Zokinvy®

Ref.: Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”) read with SEBI Circular dated July 13, 2023

Dear Sir / Madam,

Sentynl Therapeutics Inc., USA, a wholly owned subsidiary (“**Sentynl**”) of Zydus Lifesciences Limited (“the **Company**”) has acquired worldwide proprietary rights to Zokinvy® (lonafarnib) from Eiger Biopharmaceuticals Inc., USA (“**Seller**”), pursuant to an asset purchase agreement (“**APA**”), adding to portfolio of biopharmaceuticals for rare and ultra-rare diseases.

Zokinvy® is approved in the U.S. (2020), European Union and Great Britain (2022), and Japan (2024) for the treatment of Progeria, a collection of ultra-rare, fatal, genetic premature aging diseases that accelerate mortality in young patients.

Necessary details as stipulated under regulation 30 of the Listing Regulations read with para 5 of Part II of the SEBI Circular dated July 13, 2023 are provided in **Annexure-“1”**.

Please find the same in order.

Thanking you,

Yours faithfully,

For, **Zydus Lifesciences Limited**

Dhaval N. Soni
Company Secretary

Encl.: As above

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Annexure-“1”

Sr. No.	Particulars	Responses
a.	name(s) of parties with whom the agreement is entered	Sentynl Therapeutics Inc., a wholly owned subsidiary in USA and Eiger Pharmaceuticals Inc., USA.
b.	purpose of entering into the agreement	For acquisition of worldwide proprietary rights to Zokinvy®.
c.	size of agreement	Consideration payable to the Seller for acquisition of these rights: Net base price of USD 45.2 million, subject to certain purchase price adjustments, including a reduction of USD 0.10 million per diem (day) if the sale closed after April 24, 2024.
d.	shareholding, if any, in the entity with whom the agreement is executed	None
e.	significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.	Pursuant to the APA, the assets to be acquired include Zokinvy® trademark and domain names, inventory, regulatory approvals, contracts and business records. No royalties and milestones are payable to the Seller under the APA. No other special rights are given to the Seller.
f.	whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship	The said parties are not related to promoter/promoter group/ group companies in any manner.
g.	whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”	The transaction does not fall within related party transactions.
h.	in case of issuance of shares to the parties, details of issue price, class of shares issued	Not applicable

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878





Dedicated To Life

Sr. No.	Particulars	Responses
i.	in case of loan agreements, details of lender/borrower, nature of the loan, total amount of loan granted/taken, total amount outstanding, date of execution of the loan agreement/sanction letter, details of the security provided to the lenders / by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis	Not applicable
j.	any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.	No nominee director is appointed on the board of the Company and there is no conflict of interest arising out of the said transaction.
k.	in case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s)	Not applicable
i.	name of parties to the agreement	
ii.	nature of the agreement	
iii.	date of execution of the agreement	
iv.	details of amendment and impact thereof or reasons of termination and impact thereof	

For, **Zydus Lifesciences Limited**

Dhaval N. Soni
Company Secretary

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878

